Oncimmune’s intimate understanding of the human immune system enables the Company to harness its sophisticated response to disease to detect cancer earlier and to support the development of better therapies.

The key to improving cancer survival is early detection and optimal selection for therapy. Oncimmune is driven by a passion to improve cancer survival and to give people extra time. Oncimmune's immuno-diagnostic test, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis.

The unique combination of our core technology and understanding of the immune system, powers our ImmunoINSIGHTS service; a proprietary platform that enables life-science organisations to optimise drug development and delivery, leading to more effective, targeted as well as safer treatments for patients.​

Oncimmune was founded in 2002 and launched its platform diagnostic technology in 2009, followed by the launch of its first commercial tests, EarlyCDT Lung and EarlyCDT Liver. To date, over 200,000 tests have been performed for patients worldwide. EarlyCDT Lung was also used in what is believed to be the largest randomised controlled trial for the early detection of lung cancer using biomarkers, the successful NHS Early detection of Cancer of the Lung (ECLS) trial of 12,209 high-risk smokers in Scotland. This trial demonstrated that EarlyCDT Lung reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice.

Headquartered at its laboratory facility in Nottingham, UK, Oncimmune has a discovery research centre in Dortmund, Germany and in London, UK and a partner representative office in Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

Contact Oncimmune via their website

News archive

25/03/2021   Oncimmune Announces Successful Equity Placing of £9.0 million...more
19/01/2021   Oncimmune:Extra Time Podcast in Conversation with Dr James Jett...more

06/10/2020   Oncimmune and Medicines Discovery Catapult awarded funding for COVID-19 research...more
30/07/2020   Listen to Oncimmune's Extra Time podcast with Frank Sullivan...more
29/07/2020   Listen to Oncimmune's Extra Time podcast with Richard Sloggett...more
16/07/2020   Oncimmune: Beating cancer by early detection and personalised treatment...more
05/07/2020   Oncimmune in the news after successful trials in Scotland ...more

01/11/2019   Oncimmune and Biodesix, Inc. start commercialisation of EarlyCDT® Lung in the US...more
23/09/2019   Oncimmune makes key appointments to further strengthen management teams...more
20/09/2019   Oncimmune announces €8.5m credit facility secured...more
09/08/2019   Positive trial results demonstrate potential of Oncimmune's Early CDT Lung test...more
03/08/2019   Oncimmune co-funded ECLS study recognised in top seven abstracts by IASLC...more
04/07/2019   Oncimmune signs commercialisation partnership in Russia...more
28/06/2019   Oncimmune Announes Commercialisation Agreement with Biodesix...more
04/06/2019   Oncimmune announces Positive Results for Early Cancer Detection Test...more
15/05/2019   Oncimmune Announces Regulatory Approval in Israel for EarlyCDT®—Lung...more
10/05/2019   Oncimmune Announces Multi-Centre Trial of EarlyCDT®—Lung in China...more

05/04/2019   Oncimmune Announces EarlyCDT®—Lung Distribution in Portugal...more

02/04/2019   Oncimmune appoints Dr Parag Mallick to Scientific Board...more
01/04/2019   Oncimmune Announces Registration of EarlyCDT^®‐Lung in Columbia...more
19/03/2019   Oncimmune Announces Acquisition of Protagen Diagnostics AG...more
13/02/2019   Oncimmune publishes half year results to Nov 2018...more
14/01/2019   Oncimmune to host Science Day at the Royal Institution...more

27/11/2018   Oncimmune's Early Lung Cancer Test Now Covered by MultiPlan...more
25/09/2018   Oncimmune Demonstrates Early Lung Cancer Detection Test at IASLC World Conference...more
13/09/2018   Oncimmune USA LLC Appoints Marco Casarin as General Manager...more
24/05/2018   Oncimmune Study Shows Cost-Effectiveness of EarlyCDT®-Lung Test...more
14/05/2018   Oncimmune Launches EarlyCDT®-Liver Test in the US...more
20/04/2018   Oncimmune joins the BioPartner programme...more

The BioPartner Programme

BPP members enjoy our full range of discounts, enhanced promotion on BioPartner UK Delegations and first refusal on new international opportunities.

Not a member? Join the BioPartnership Programme

BioPartner UK is a member of

Sponsors Alliance

Prompt Payment Code